When was Innorna founded?

Innorna was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Innorna located?

Innorna is headquartered in Shenzhen, China.

Is Innorna a funded company?

Innorna is a funded company, having raised a total of $120M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 28, 2021.

When was the latest funding round of Innorna?

Innorna's latest funding was a $***** Series B round on Mar 30, 2022, with participation from 3 investors. Its primary sector is Drug Delivery. In China, the Drug Delivery sector has seen $118M in funding in 2026 to date.

Where does Innorna rank among its competitors?

Innorna ranks 4th amongst 8 active competitors, of which 5 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was ReCode Therapeutics, which secured an undisclosed amount in Aug, 2026.

Who are the top competitors of Innorna?

Innorna's top competitors include Strand Therapeutics, ReCode Therapeutics and Arcturus Therapeutics. Among them, ReCode Therapeutics secured the most recent funding round in August, 2026.

Innorna - 2026 Company Profile, Team, Funding & Competitors

Innorna is a series B company based in Shenzhen (China), founded in 2019. It operates as a Developer of RNA medicine technologies, including delivery and mRNA engineering. Innorna has raised $120M in funding from investors like CDH, Legend Capital and Chongqing Zhifei Biological Products. The company has 8 active competitors, including 5 funded and 1 that has exited. Its top competitors include companies like Strand Therapeutics, ReCode Therapeutics and Arcturus Therapeutics.

Company Details

Developer of RNA medicine technologies, including delivery and mRNA engineering. The company focuses on advancing delivery technology platforms and mRNA engineering platforms. It explores co-development programs and pipeline asset out-licensing. The company supports in vivo, ex vivo, and in vitro platforms. It targets prophylactic vaccines, cancer vaccines, and various tissues.

Key Metrics

Founded Year

2019

Location

Shenzhen, China

Stage

Series B

Total Funding

$120M in 2 rounds

Latest Funding Round

Series B, Mar 30, 2022, $*****

Investors

CDH & 6 more

Ranked

4^th among 8 active competitors

Similar Companies

Strand Therapeutics & 6 more

View Innorna's full profile

Innorna has raised a total funding of $120M over 2 rounds. Its first funding round was on Jul 28, 2021. Its latest funding round was a Series B round on Mar 30, 2022 for $*****. 3 investors participated in its latest round. Innorna has 7 institutional investors.

Here is the list of recent funding rounds of Innorna:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 30, 2022	4206756	Series B	3159075	2440072	1864862	6140067
Jul 28, 2021	6294561	Series A	7073478	3602502	Legend Capital & 2 more	3740905

Access funding benchmarks and valuations. Sign up today!

View details of Innorna's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Innorna include Strand Therapeutics, ReCode Therapeutics and Arcturus Therapeutics. Here is the list of Top 10 competitors of Innorna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
2nd	ReCode Therapeutics 2015, Menlo Park (United States), Series B	Developer of precision medicines for treating lung related diseases	$371M	Sanofi Ventures, Cystic Fibrosis Foundation ... & 17 others	64/100
3rd	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	56/100
4th	Innorna 2019, Shenzhen (China), Series B	Developer of RNA medicine technologies, including delivery and mRNA engineering	$120M	CPE, China Renaissance Group & 5 others	48/100
5th	Starna Therapeutics 2021, Suzhou (China), Series B	Developer of RNA-based drugs for multiple diseases	$66.1M	LYFE Capital, Primavera & 6 others	44/100
6th	Averna Therapeutics Watertown (United States), Series A	Developer of RNAand lipid nanoparticle-based genomic medicines to treat multiple diseases by inserting genes	$85M	Delos Capital, Novartis Venture Fund & 8 others	33/100
7th	XULAB 2024, Medford (United States), Unfunded	Provider of drug delivery systems for advanced therapeutic discovery	-	-	16/100
8th	Nava Therapeutics 2022, Cambridge (United States), Unfunded	Developer of RNA delivery technologies using novel lipid nanoparticles	-	-	16/100